Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Lyfe Rx
WARNING LETTER
•Lyfe Rx•August 31, 2025

Lyfe Rx – FDA Warning Letter, Aug 31, 2025

Record Details

The FDA issued a warning letter to Lyfe Rx on September 9, 2025, following a review of their website in August 2025. The inspection revealed that Lyfe Rx offers compounded drug products, specifically semaglutide and tirzepatide, with claims that are considered false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA). These claims suggest that the products are equivalent to FDA-approved drugs, which they are not, resulting in the products being misbranded and introduced into interstate commerce in violation of section 301(a) of the FDCA.

The FDA highlighted that compounded drug products are not FDA-approved and that the claims made on Lyfe Rx"s website, such as "Clinically Proven Weight Loss," are misleading. The letter serves as a notice of these violations and emphasizes that it is not an exhaustive list of potential issues. Lyfe Rx is required to investigate and address these violations to prevent recurrence. The company must respond within 15 working days, detailing the steps taken to rectify the issues and prevent future violations. Failure to comply may result in legal actions, including product seizure and injunctions. The FDA also warns that misbranded products may be detained or refused entry into the U.S. if Lyfe Rx is operating internationally.

Company
Lyfe Rx
Inspection date
August 31, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • George Tidmarsh (Director)
View Company Profile

ID · dc25e7b2-0ab6-41ca-9265-567a9d39e199

Violation Codes8
FD&C Act 502(a)FD&C Act 502(b)21 U.S.C. 352(a)21 U.S.C. 352(bb)FD&C Act 301(a)FD&C Act 301(c)21 U.S.C. 331(c)21 U.S.C. 331(a)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Lyfe Rx
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.